Literature DB >> 15855576

Anemia and diabetes in the absence of nephropathy.

Kathrine J Craig1, John D Williams, Stephen G Riley, Hilary Smith, David R Owens, Debbie Worthing, Ivor Cavill, Aled O Phillips.   

Abstract

OBJECTIVE: Patients with diabetes commonly have a greater degree of anemia for their level of renal impairment than those presenting with other causes of renal failure. To clarify the contribution and differing roles of diabetes and nephropathy in the development of anemia in diabetic patients, we examined the hematologic and hematinic parameters of diabetic patients without nephropathy. RESEARCH DESIGN AND METHODS: The study group was comprised of 62 patients with type 2 diabetes who had been followed for a median of 7 years. For the study, these patients had additional samples taken during their annual routine blood testing for the measurement of extra parameters, including serum ferritin, serum erythropoietin (Epo) levels, and the percentage of reticulocytes. These measurements were combined with the routine parameters Hb, hematocrit, HbA(1c), and glomerular filtration rate.
RESULTS: In all, 8 of the 45 male patients (17.8%) and 2 of the 17 female patients (11.8%) were classified as anemic (Hb <13g/dl and <11.5g/dl, respectively). Although only a small number of the patients had anemia as defined by normal values, a retrospective analysis of individual patients over time revealed a sustained though small decrease in Hb from initial presentation. A statistically significant difference in Epo levels (P = 0.016 by Kruskal-Wallis test) was observed from the group with the lowest (Hb < or =11.5) to that with the highest (Hb > or =14.5) Hb values, with a median Epo value of 37 (interquartile range 24-42) vs. 13 (9-15) IU/l, respectively. In contrast, there was no evidence of an increased reticulocyte response to higher levels of Epo (r = 0.134 [Pearsons], P = 0.36). Reticulocyte counts ranged from 44 (38-57) to 76.5 (56-83) in the lowest and highest Hb groups, respectively.
CONCLUSIONS: Although only a small number of subjects in the group were overtly anemic, all subjects had an ongoing, small but significant decrease in Hb since presentation. This study of diabetic patients without nephropathy shows an expected increase in Epo production in response to lowering levels of Hb but without the expected reticulocyte response.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15855576     DOI: 10.2337/diacare.28.5.1118

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  36 in total

1.  Lower haemoglobin level and subsequent decline in kidney function in type 2 diabetic adults without clinical albuminuria.

Authors:  T Babazono; K Hanai; K Suzuki; Y Kiuchi; A Inoue; M Tanaka; N Tanaka; M Hase; A Ishii; Y Iwamoto
Journal:  Diabetologia       Date:  2006-04-13       Impact factor: 10.122

Review 2.  Anaemia in diabetes: Is there a rationale to TREAT?

Authors:  M C Thomas; M E Cooper; K Rossing; H H Parving
Journal:  Diabetologia       Date:  2006-04-04       Impact factor: 10.122

3.  Prediction of proliferative diabetic retinopathy with hemoglobin level.

Authors:  Baqiyyah N Conway; Rachel G Miller; Ronald Klein; Trevor J Orchard
Journal:  Arch Ophthalmol       Date:  2009-11

4.  The relationship between hemoglobin levels and endothelial functions in diabetes mellitus.

Authors:  Alper Sonmez; Mahmut Ilker Yilmaz; Mutlu Saglam; Selim Kilic; Tayfun Eyileten; Gokhan Uckaya; Kayser Caglar; Yusuf Oguz; Abdulgaffar Vural; Mujdat Yenicesu; Mustafa Kutlu; Can Kinalp; Carmine Zoccali
Journal:  Clin J Am Soc Nephrol       Date:  2009-10-15       Impact factor: 8.237

5.  Diabetes mellitus increases the prevalence of anemia in patients with chronic kidney disease: A nested case-control study.

Authors:  Charalampos Loutradis; Alexandra Skodra; Panagiotis Georgianos; Panagiota Tolika; Dimitris Alexandrou; Afroditi Avdelidou; Pantelis A Sarafidis
Journal:  World J Nephrol       Date:  2016-07-06

Review 6.  Erythropoietic stress and anemia in diabetes mellitus.

Authors:  Dhruv K Singh; Peter Winocour; Ken Farrington
Journal:  Nat Rev Endocrinol       Date:  2009-04       Impact factor: 43.330

7.  Erythropoietin and its carbamylated derivative prevent the development of experimental diabetic autonomic neuropathy in STZ-induced diabetic NOD-SCID mice.

Authors:  Robert E Schmidt; Karen G Green; Dongyan Feng; Denise A Dorsey; Curtis A Parvin; Jin-Moo Lee; Qinlgi Xiao; Michael Brines
Journal:  Exp Neurol       Date:  2007-10-29       Impact factor: 5.330

8.  A non-erythropoietic peptide derivative of erythropoietin decreases susceptibility to diet-induced insulin resistance in mice.

Authors:  M Collino; E Benetti; M Rogazzo; F Chiazza; R Mastrocola; D Nigro; J C Cutrin; M Aragno; R Fantozzi; M A Minetto; C Thiemermann
Journal:  Br J Pharmacol       Date:  2014-11-24       Impact factor: 8.739

9.  Hemoglobin and overt nephropathy complications in type 1 diabetes.

Authors:  Baqiyyah Conway; Linda Fried; Tevor Orchard
Journal:  Ann Epidemiol       Date:  2008-02       Impact factor: 3.797

10.  Impact of diabetes on haemoglobin levels in renal disease.

Authors:  R Ravanan; J R Spiro; P W Mathieson; R M Smith
Journal:  Diabetologia       Date:  2006-11-28       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.